{
    "organizations": [],
    "uuid": "ef452514ccf488edb2a17dfcd08e9400a79d072a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-catalyst-pharma-submits-nda-for-fi/brief-catalyst-pharma-submits-nda-for-firdapse-idUSFWN1RB0IN",
    "ord_in_thread": 0,
    "title": "Catalyst Pharma Submits NDA For Firdapse",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29 (Reuters) - Catalyst Pharmaceuticals Inc:\n* CATALYST PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR FIRDAPSEÂ® FOR TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME\n* CATALYST PHARMACEUTICALS - SUBMISSION OF NDA TO U.S. FDA FOR FIRDAPSE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-29T20:21:00.000+03:00",
    "crawled": "2018-03-30T13:30:53.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "catalyst",
        "pharmaceutical",
        "inc",
        "catalyst",
        "pharmaceutical",
        "announces",
        "submission",
        "new",
        "drug",
        "application",
        "treatment",
        "myasthenic",
        "syndrome",
        "catalyst",
        "pharmaceutical",
        "submission",
        "nda",
        "fda",
        "firdapse",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}